|1.||Hersey, Peter: 3 articles (02/2006 - 10/2003)|
|2.||Zhang, Xu Dong: 3 articles (02/2006 - 10/2003)|
|3.||Borrow, Jodie M: 2 articles (04/2004 - 10/2003)|
|4.||Gillespie, Susan K: 2 articles (04/2004 - 10/2003)|
|5.||Qian, Wen-bin: 1 article (09/2012)|
|6.||Xu, Yan-hua: 1 article (09/2012)|
|7.||Yang, Chun-mei: 1 article (09/2012)|
|8.||Gillespie, Susan: 1 article (02/2006)|
|9.||Borrow, Jodie: 1 article (02/2006)|
|10.||Wu, Jing Jing: 1 article (02/2006)|
|1.||Melanoma (Melanoma, Malignant)
04/01/2004 - "In the present study, we have examined a new HDAC inhibitor, suberic bishydroxamate (SBHA), for its effect on a panel of human melanoma cell lines. "
10/15/2003 - "Suberic bishydroxamate (SBHA) is a relatively new HDAC inhibitor that induced apoptosis in the majority of melanoma cell lines through a mitochondrial and caspase-dependent pathway. "
04/01/2004 - "The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells."
10/15/2003 - "The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis."
02/15/2006 - "TRAIL-resistant melanoma cells are cross-resistant to apoptosis induced by another death ligand FasL, the DNA-damaging agent cisplatin, the histone deacetylase inhibitor suberic bishydroxamate, and the antimicrotubule Vinca alkaloid, vincristine. "
|2.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
|1.||Histone Deacetylase Inhibitors
|2.||TNF-Related Apoptosis-Inducing Ligand
|4.||DNA (Deoxyribonucleic Acid)